Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Drug Makers Face Hit Over Former Excise Duty

This article was originally published in PharmAsia News

Executive Summary

Many pharmaceutical companies in India could be faced with punitive action because they did not act quickly enough in passing on duty cuts. The National Pharmaceutical Pricing Authority rejected the industry's request they be allowed to sell out all drugs assessed at the old excise duty rate before applying the new one. The companies noted the law bars them from changing the price on drugs already packaged and ready for distribution. India's revenue department could decide to let the firms pass on the earlier excise taxes on drugs in the chain for distribution at the time of the duty change. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068178

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel